TY - EJOU
AU - Perna, Angelica
AU - Lucariello, Angela
AU - Sellitto, Carmine
AU - Agliata, Iolanda
AU - Carleo, Maria Aurora
AU - Sangiovanni, Vincenzo
AU - Esposito, Vincenzo
AU - Guerra, Germano
AU - Cobellis, Luigi
AU - Luca, Antonio De
TI - Different Cell Cycle Modulation in SKOV-3 Ovarian Cancer Cell Line by Anti-HIV Drugs
T2 - Oncology Research
PY - 2017
VL - 25
IS - 9
SN - 1555-3906
AB - Antiretroviral drugs used for the treatment of human immunodeficiency virus (HIV) have proven to be effective even against cancer. Drawing from this background, the aim of our research project was to evaluate the
effects of anti-HIV drugs that belong to the nucleoside and nucleotide reverse transcriptase inhibitor [NRTI;
abacavir (ABC) and tenofovir (TDF)], nonnucleoside reverse transcriptase inhibitor [NNRTI; efavirenz (EFV)
and etravirine (ETR)], and protease inhibitor [PI; darunavir (DRV)] categories on ovarian adenocarcinoma cell
line SKOV-3. Using FACS analysis, we observed that treatment with NRTIs and NNRTIs showed a block in
the G0/G1 phase. In particular, ETR displayed a relevant block in the progression of the G0/G1 phase of the cell
cycle compared with the other examined drugs, and it also induced differentiation of SKOV-3 cells. In contrast,
FACS analysis demonstrated that ABC and the PI inhibitor DRV showed no effect on the proliferation of cancer
cells. DAPI (4',6-diamidino-2-phenylindole) staining demonstrated that cells treated with NNRTIs (EFV and
ETR) presented more DNA damage compared with other treatments. Immunoblotting analysis demonstrated
that TDF, EFV, and ETR were able to obtain a reduction in the expression of cyclin D1 and Rb hypophosphorylation, and an increase in p21 concentration. Finally, we observed that ETR also induced differentiation,
as demonstrated by Western blot, with high levels of E-cadherin expression. Therefore, our study provides
additional evidence supporting the in vitro cytotoxic effects of ETR and EFV. Furthermore, it promotes the
hypothesis for their potential use as therapeutic agents in ovarian cancer.
KW - Cell cycle; Ovarian cancer; Antiretroviral drugs; Antineoplastic effect
DO - 10.3727/096504017X14905635363102